Monthly nephrology bulletin — November 8, 2026
Period covered: October 9 to November 8, 2026. The month was dominated by ASN Kidney Week (Denver, October 22–25): four phase 3 trials in IgA nephropathy, a new FDA accelerated approval, and several negative pragmatic trials that are as worth knowing as the positive ones. Thirteen verified items.
Chronic kidney disease and kidney protection
1. ATTACK: aspirin for primary prevention in CKD, no proven benefit
[Congress] [United Kingdom]
Pragmatic open-label randomized primary-care trial presented at Kidney Week: 4,633 adults with CKD G1–G4 and no prior cardiovascular disease, aspirin 75 mg/day vs no aspirin, mean follow-up 3.1 years. Major cardiovascular events 2.4% vs 3.3% (SHR 0.73; 95% CI 0.52–1.03); major bleeding 29 vs 19 events (SHR 1.54; 95% CI 0.86–2.74); mortality 5.4% vs 4.9%. No result was statistically significant. Funded by the NIHR and the British Heart Foundation.
Why it matters: enrollment fell far short of the planned 25,210 (COVID-19), so the trial is underpowered and its result is also consistent with no effect (abstract FR-OR100, per HCPLive). The trial does not provide sufficient evidence to start routine aspirin for primary prevention in CKD.
Sources
- [Coverage] HCPLive, October 23, 2026. https://www.hcplive.com/view/attack-should-patients-with-ckd-start-aspirin-for-primary-prevention-
- [Coverage] Healio, October 29, 2026. https://www.healio.com/news/nephrology/20261029/lowdose-aspirin-not-linked-to-major-cv-event-risk-reduction-vs-usual-care-in-ckd
- [Registry] NCT03796156, ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03796156
2. Liberalizing potassium from fruits and vegetables did not raise mean serum potassium in a small trial in advanced CKD
[Congress] [Canada]
Open-label randomized crossover trial (Kidney Week poster TH-PO1247) in 30 selected participants from Winnipeg with eGFR 15–45 mL/min/1.73 m² and serum potassium 4.5–5.5 mEq/L: after a two-week liberalized run-in, a diet with 2,000 mg/day of potassium from fruits and vegetables vs a 500 mg/day restricted diet, six weeks each. No difference in mean serum potassium was detected at six weeks (mean difference −0.014 mEq/L; 95% CI −0.199 to 0.171; P = .875), with significantly higher urinary potassium excretion. One hyperkalemia event occurred during the liberalized diet versus none during restriction, and two during run-in.
Why it matters: supports the trend away from blanket bans on fruits and vegetables, but it is a small, short study, presented only as a poster and without long-term safety data; it cannot be generalized to all advanced CKD and does not yet change practice.
Sources
- [Coverage] HCPLive, October 23, 2026. https://www.hcplive.com/view/does-ckd-require-restricting-potassium-rich-foods-with-navdeep-tangri-md
Dialysis and vascular access
3. SIMPLIFIED: high-dose cholecalciferol in dialysis did not improve survival
[Congress] [United Kingdom]
Pragmatic 1:1 randomized trial across 55 UK dialysis units, with outcomes drawn from routine healthcare data, presented as abstract FR-OR101 at ASN Kidney Week 2026: more than 3,800 dialysis patients received cholecalciferol 60,000 IU every two weeks or standard care. According to the ASN press release, cholecalciferol did not significantly reduce all-cause mortality (the primary outcome) compared with standard care; the same release mentions a possible benefit in non-White participants and in men, from subgroup analyses.
Why it matters: negative primary result; the presenting investigator described the subgroups as hypothesis-generating. It does not justify high-dose vitamin D to reduce mortality.
Sources
- [Meeting] Smith RM, Cui M, et al. "High-Dose Cholecalciferol and Clinical Outcomes in Patients Receiving Dialysis: Results of the SIMPLIFIED Trial." ASN Kidney Week 2026, abstract FR-OR101, October 23, 2026 (official late-breaking abstract list). https://www.asn-online.org/education/kidneyweek/2026/KW26_LBAs_TitlesAuthors.pdf
- [Official release] ASN, October 23, 2026. https://www.asn-online.org/about/press/releases/ASN_PR_20261023_2026KidneyWeekTrial.pdf
- [Coverage] Healio, October 30, 2026. https://www.healio.com/news/nephrology/20261030/highdose-vitamin-d-does-not-improve-survival-on-dialysis
- [Coverage] News-Medical, October 24, 2026. https://www.news-medical.net/news/20261024/Kidney-Week-2026-features-late-breaking-clinical-trials-in-kidney-care.aspx
- [Registry] ISRCTN15087616, ISRCTN. https://www.isrctn.com/ISRCTN15087616
4. VOCAL: three-times-weekly vadadustat noninferior to pegylated epoetin in hemodialysis
[Industry] [United States]
Topline results (manufacturer press release, Akebia, November 5): open-label 1:1 randomized trial in 353 in-center hemodialysis patients (18 clinics), vadadustat three times weekly (an investigational regimen) vs Mircera. Hemoglobin change at weeks 20–24: difference −0.45 g/dL (95% CI −0.71 to −0.19), within the −0.75 g/dL noninferiority margin. Serious adverse events 159.7 vs 183.9 per 100 patient-years, which the company describes as similar.
Why it matters: manufacturer press-release data, not peer reviewed; in-session dosing may simplify adherence, but hemoglobin was numerically lower and 24 weeks cannot answer the cardiovascular safety question surrounding HIF-PH inhibitors.
Sources
- [Official release] Akebia Therapeutics (reproduced on Finviz), November 5, 2026. https://finviz.com/news/416732/akebia-therapeutics-reports-positive-topline-data-from-vocal-trial-showing-vadadustat-dosed-tiw-met-primary-endpoint-of-non-inferiority-to-esa-in-maintaining-hemoglobin
- [Coverage] BioPharmaWatch (reproducing Akebia's press release), November 5, 2026. https://www.biopharmawatch.com/news/AKBA/akebia-vocal-trial-positive-results-vadadustat
- [Registry] NCT06901505, ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06901505
5. V012: acellular tissue-engineered vessel vs fistula in women on catheter hemodialysis
[Congress] [United States]
Randomized 1:1 phase 3 trial presented at Kidney Week 2026 (Humacyte had announced the topline results on June 10, 2026): women on catheter hemodialysis who were eligible for fistula creation; prespecified interim analysis of the first 80 to complete 12 months, 40 per arm. Catheter-free days over 12 months: 220 vs 129 with AVF (difference 91 days; 95% CI 40–142; P < .001); mean maturation 1.7 vs 5.3 months; dialysis access-related infections, including catheter infections, 5.1% vs 15%. More thrombosis (20 vs 8 events) and stenosis (43 vs 36) with the graft; 12-month secondary patency not significantly different (78% vs 63%).
Why it matters: it could be an alternative for women, whose fistulas mature less often, but this is a small interim analysis with more thrombosis and stenosis events in the graft, and no results were presented for a subgroup of women with small veins; the product is investigational for this use and not available in the region.
Sources
- [Coverage] HCPLive, October 27, 2026. https://www.hcplive.com/view/bioengineered-vessel-adds-91-catheter-free-days-for-women-on-dialysis
- [Official release] Humacyte, June 10, 2026. https://investors.humacyte.com/news-releases/news-release-details/humacyte-atev-met-superiority-primary-endpoint-compared-standard
6. RENEW-HD: portable sorbent hemodialysis, first safety data
[Congress] [Europe]
Prospective open-label single-arm pivotal study at four European centers, with in-center assisted treatment, funded by Nextkidney (Neokidney portable system). According to the abstract, as of the August 31, 2026 cutoff, 29 participants completed 474 sessions (95% of planned) without serious adverse device effects and without hyperammonemia; sodium and bicarbonate were generally stable over four weeks; one sorbent exhaustion, correctly detected. Mean single-pool Kt/V 0.74 per two-hour session. According to updated data the investigator discussed in the HCPLive interview, five sessions ended early because of cartridge exhaustion alarms, and mean weekly standardized Kt/V was 2.19 (not accounting for residual kidney function).
Why it matters: a manufacturer-funded, in-center, assisted feasibility study without a comparator; interesting for future home dialysis, no immediate practical impact.
Sources
- [Coverage] HCPLive, October 24, 2026. https://www.hcplive.com/view/renew-hd-portable-hemodialysis-data-with-karin-gerritsen-md-phd
Kidney transplantation
7. Imlifidase in highly sensitized deceased-donor recipients: 90% graft failure-free at one year
[Congress] [Europe]
European post-authorization efficacy and safety study (PAES), controlled, non-randomized, open-label, presented at Kidney Week; according to the sponsor's release, 50 highly sensitized, crossmatch-positive deceased-donor recipients treated with imlifidase (Idefirix) in the analysis presented at ASN. One-year graft failure-free survival 90%, graft survival 92%, and patient survival 98%. Antibody-mediated rejection occurred in 56% of recipients, with no graft loss associated with that rejection.
Why it matters: confirms registration-study results in European practice, but without randomization and with data released by the manufacturer (Hansa Biopharma); the drug is not registered in the Dominican Republic and is very expensive.
Sources
- [Official release] Hansa Biopharma, October 23, 2026. https://www.inderes.fi/releases/hansa-biopharma-ab-hansa-biopharma-announces-positive-idefirix-paes-results-presented-in-the-high-impact-clinical-trials-session-at-asn-kidney-week
- [Coverage] HCPLive, October 28, 2026. https://www.hcplive.com/view/imlifidase-opens-a-transplant-window-with-oriol-bestard-md-phd
8. Pregnancy after living kidney donation: more hospitalizations for hypertensive disorders of pregnancy
[Publication] [Canada]
Population-based matched cohort (JAMA, published online October 22) from Ontario, British Columbia, and Alberta: 385 pregnancies in 252 living donors vs 1,540 nondonor pregnancies. Hospitalization with gestational hypertension, preeclampsia, or eclampsia: 11.9% versus 8.3% (RR 1.51; 95% CI 1.10–2.08); small-for-gestational-age births were also more common (RR 1.86; 95% CI 1.37–2.52).
Why it matters: useful for informed consent of young donors and their obstetric follow-up; observational, and the absolute excess risk is moderate.
Sources
- [Coverage] HCPLive, October 22, 2026. https://www.hcplive.com/view/pregnancy-after-living-kidney-donation-with-amit-x-garg-md-phd
- [Article] Wang C, Naylor KL, McArthur E, et al. "Pregnancy Outcomes After Living Kidney Donation." JAMA. 2026. DOI: 10.1001/jama.2026.21737. https://doi.org/10.1001/jama.2026.21737
- [Coverage] Healio, October 23, 2026. https://www.healio.com/news/nephrology/20261023/most-pregnancies-after-living-kidney-donation-uncomplicated
Glomerular disease and acute kidney injury
9. FDA: accelerated approval of ravulizumab for IgA nephropathy
[Regulatory FDA] [United States]
On October 21, 2026, according to AstraZeneca, the FDA granted accelerated approval to ravulizumab (Ultomiris), a C5 inhibitor. According to the FDA prescribing information (revised October 2026), it is indicated to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression; the indication is approved under accelerated approval based on reduction of proteinuria, it has not been established whether ravulizumab slows kidney function decline, and continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial. In the interim analysis of the phase 3 I CAN trial (352 patients, 176 per group, of 485 randomized; NEJM, October 23), UPCR fell 43.4% vs placebo at week 34 (99% CI 30.1–54.2 in the article; the manufacturer's release gives 95% CI 33.5–51.8).
Why it matters: according to the manufacturer it is the first and only C5 inhibitor indicated in IgAN, but approval rests on a surrogate endpoint and no kidney benefit has yet been shown; the I CAN eGFR endpoint comes at week 106. Intravenous infusion, a boxed warning for serious meningococcal infections, and a REMS program (ULTOMIRIS and SOLIRIS REMS) per the prescribing information (vaccination was required before treatment in the trial), and very high cost limit its use in our setting.
Sources
- [Regulator] FDA, Ultomiris (ravulizumab-cwvz) prescribing information, revised October 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761108s046lbl.pdf
- [Official release] AstraZeneca, October 22, 2026. https://www.inderes.se/en/releases/astrazeneca-ultomiris-received-accelerated-approval-in-the-us-as-first-and-only-c5-complement-inhibitor-to-reduce-proteinuria-in-adults-with-primary-immunoglobulin-a-nephropathy
- [Coverage] Healio, October 22, 2026. https://www.healio.com/news/nephrology/20261022/fda-approves-ultomiris-for-proteinuria-reduction-in-adults-with-primary-iga-nephropathy
- [Coverage] HCPLive, October 22, 2026. https://www.hcplive.com/view/ravulizumab-receives-fda-accelerated-approval-for-iga-nephropathy
- [Coverage] HCPLive, October 23, 2026. https://www.hcplive.com/view/i-can-ravulizumab-cuts-proteinuria-43-vs-placebo-in-iga-nephropathy
- [Article] Barratt J, Farag YMK, Rice K, et al. N Engl J Med. 2026. DOI: 10.1056/NEJMoa2607544. https://doi.org/10.1056/NEJMoa2607544
10. RAINIER: povetacicept halves proteinuria in IgA nephropathy
[Clinical trial] [International]
Interim analysis of a randomized, double-blind phase 3 trial (NEJM, October 23); interim efficacy was analyzed in the first 199 participants (131 povetacicept, 68 placebo): UPCR −52.0% vs −4.3% with placebo at week 36 (adjusted difference −49.8 percentage points; 95% CI −58.6 to −39.2; P < .001); UPCR < 0.5 g/g in 42% vs 6%; galactose-deficient IgA1 −77.4% vs +9.1%; hematuria resolution, among those with hematuria at baseline, 85% vs 23%. Vertex reports November 30, 2026 as the FDA target action date for accelerated approval.
Why it matters: a large effect on proteinuria, but only at 36 weeks and in a manufacturer-sponsored trial (Vertex); eGFR slope will be assessed at week 104, and long-term safety is still missing.
Sources
- [Article] N Engl J Med. 2026. DOI: 10.1056/NEJMoa2608682. https://www.nejm.org/doi/full/10.1056/NEJMoa2608682
- [Official release] Vertex Pharmaceuticals, October 23, 2026. https://investors.vrtx.com/news-releases/news-release-details/phase-3-rainier-results-supporting-best-class-potential
- [Coverage] HCPLive, October 23, 2026. https://www.hcplive.com/view/rainier-povetacicept-cuts-proteinuria-gd-iga1-in-iga-nephropathy
- [Coverage] AJMC, October 24, 2026. https://www.ajmc.com/view/povetacicept-cuts-proteinuria-by-52-in-iga-nephropathy-at-week-36
11. TELIGAN: telitacicept preserves eGFR over two years in IgA nephropathy
[Congress] [China]
Randomized phase 3 trial in 318 Chinese adults (159 per group) with biopsy-confirmed IgA nephropathy: subcutaneous telitacicept 240 mg or placebo once weekly through week 39, then every two weeks through week 104. According to abstract TH-OR111 at ASN Kidney Week 2026 (funded by RemeGen), annualized eGFR slope was −0.6 vs −5.7 mL/min/1.73 m² per year (difference 5.1; 95% CI 3.5–6.7; P < .001), confirmed eGFR decline ≥ 30% occurred in 2.5% vs 16.4% (HR 0.11; 95% CI 0.04–0.30), and serious adverse events in 8.2% vs 18.2%. According to Vor Bio's release, which attributes the data to the sponsor RemeGen, UPCR changed −60.3% from baseline with telitacicept vs +0.9% with placebo at week 104, and injection-site reactions occurred in 56% vs 18.9%.
Why it matters: it provides a two-year kidney function outcome rather than proteinuria alone; but the population is exclusively Chinese, the placebo arm lost function strikingly fast, the two-year data have only been presented at a congress (the 39-week results were published in NEJM in May 2026), and no FDA filing has been announced.
Sources
- [Meeting] Lv J, Liu L, et al. "Telitacicept for IgA Nephropathy: Final Two-Year Results of the Phase 3 TELIGAN Trial." ASN Kidney Week 2026, abstract TH-OR111, October 22, 2026 (official late-breaking abstract list). https://www.asn-online.org/education/kidneyweek/2026/KW26_LBAs_TitlesAuthors.pdf
- [Coverage] HCPLive, October 22, 2026. https://www.hcplive.com/view/teligan-telitacicept-preserves-egfr-through-2-years-in-iga-nephropathy
- [Official release] Vor Bio (distributed by GlobeNewswire; reproduced on Finviz), October 22, 2026. https://finviz.com/news/406799/telitacicept-demonstrates-durable-preservation-of-kidney-function-through-two-years-in-phase-3-teligan-trial-in-iga-nephropathy
12. IMAgINATION: sefaxersen (antisense against factor B) meets its proteinuria endpoint
[Congress] [International]
Randomized, double-blind, placebo-controlled phase 3 trial, presented as an interim analysis (abstract FR-OR104 at ASN Kidney Week 2026). Roche reports that the trial enrolled 459 people, randomized 1:1 to sefaxersen or placebo for 105 weeks; the release does not state how many are included in the interim analysis. In that analysis, Roche reported a 43.1% reduction in 24-hour UPCR relative to placebo at week 37 (95% CI 32.5–52.0; P < .0001). eGFR will be assessed at week 105.
Why it matters: adds another pathway (alternative complement, subcutaneous) to a field crowded with surrogate-based options; without kidney function data it does not change practice.
Sources
- [Meeting] Barratt J, Floege J, et al. "Sefaxersen, a Novel mRNA-Targeted Therapy for IgA Nephropathy: Interim Analysis of the Phase 3 IMAgINATION Trial." ASN Kidney Week 2026, abstract FR-OR104, October 23, 2026 (official late-breaking abstract list). https://www.asn-online.org/education/kidneyweek/2026/KW26_LBAs_TitlesAuthors.pdf
- [Coverage] HCPLive, October 23, 2026. https://www.hcplive.com/view/imagination-sefaxersen-meets-phase-3-proteinuria-endpoint-in-iga-nephropathy
- [Official release] Roche, October 23, 2026. https://www.roche.com/media/releases/med-cor-2026-10-23
13. ICRAKI: intermittent hemodialysis vs continuous therapy in severe acute kidney injury
[Clinical trial] [France]
Randomized noninferiority trial in 42 French ICUs (NEJM, October 14), funded by the French Ministry of Health (PHRC): critically ill adults with AKI assigned to intermittent hemodialysis or continuous kidney replacement therapy. Of 554 patients randomized according to the AP-HP release, 535 were included in the analysis (260 intermittent hemodialysis and 275 continuous therapy, according to Healio). The day-90 composite kidney outcome (MAKE: death from any cause, dependence on kidney replacement therapy, or creatinine > 25% above baseline) occurred in 78.1% vs 71.6%; noninferiority was not established. Day-90 mortality was a secondary outcome: 63.1% vs 53.5% (crude proportions, according to AP-HP); in the hazard analysis, Healio reports an HR of 1.3 (95% CI 1.04–1.63) for intermittent hemodialysis. Stopped early for the mortality signal.
Why it matters: early stopping can exaggerate effects and mortality was a secondary outcome, but the result weighs against intermittent dialysis as first choice in unstable patients where continuous therapy is available; in Dominican hospitals with limited access to continuous therapy, it supports prioritizing it for the sickest patients and considering prolonged modalities.
Sources
- [Article] Gaudry S, et al. "Intermittent or Continuous Renal-Replacement Therapy in Acute Kidney Injury." N Engl J Med. 2026. DOI: 10.1056/NEJMoa2608397. https://www.nejm.org/doi/full/10.1056/NEJMoa2608397
- [Coverage] Healio, October 15, 2026. https://www.healio.com/news/nephrology/20261015/mortality-risks-higher-with-intermittent-vs-continuous-renal-replacement-therapy-in-aki
- [Official release] AP-HP, October 14, 2026. https://www.aphp.fr/espace-medias/liste-ressources-presse/insuffisance-renale-aigue-une-etude-apporte-de-nouvelles
- [Registry] NCT06032884, ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06032884
Regional note: this issue includes no in-period items from Latin America and the Caribbean.
Upcoming meetings and dates
- November 30, 2026: FDA target action date, as reported by Vertex, for the accelerated approval decision on povetacicept in IgA nephropathy.
Ready-to-paste LinkedIn post
Monthly nephrology bulletin — November 8, 2026 13 verified items from the past month, from NEJM, JAMA, and the high-impact trials at ASN Kidney Week 2026. Three worth your time: • ICRAKI (NEJM): among critically ill adults with AKI, intermittent hemodialysis did not establish noninferiority to CRRT on the composite kidney outcome, and day-90 mortality, a secondary outcome, was 63.1% vs 53.5%. Stopped early. • TELIGAN: telitacicept slowed 2-year eGFR loss in IgA nephropathy (−0.6 vs −5.7 mL/min/1.73 m² per year; n = 318). Chinese population only; the 2-year data are not yet published in a journal. • SIMPLIFIED: high-dose cholecalciferol did not improve survival in more than 3,800 dialysis patients. The possible subgroup benefit is hypothesis-generating only. Full bulletin, with a critical read of every study and links to the sources: https://boletinesmedicos.com/en/nephrology/2026-11-08.html #Nephrology #KidneyDisease #IgANephropathy #AKI #KidneyWeek
Ready-to-paste X (Twitter) post
Nephrology, Nov 2026: in severe AKI, intermittent HD had higher day-90 mortality (secondary outcome: 63.1% vs 53.5%) than CRRT (ICRAKI). Telitacicept slowed eGFR loss in IgAN (−0.6 vs −5.7 mL/min/1.73 m²/yr). https://boletinesmedicos.com/en/nephrology/2026-11-08.html
Get every issue by email
Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.